GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GTXI
CUSIP40052B10
Phone901-523-9700
Debt
Debt-to-Equity RatioN/A
Current Ratio6.05
Quick Ratio6.05
Price-To-Earnings
Trailing P/E Ratio-1.02
Forward P/E Ratio-1.10
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.78 per share
Price / Book1.01
Profitability
EPS (Most Recent Fiscal Year)($1.75)
Net Income$-30,430,000.00
Net MarginsN/A
Return on Equity-110.72%
Return on Assets-89.83%
Miscellaneous
Employees27
Outstanding Shares24,050,000
Market Cap$43.04 million
GTX (NASDAQ:GTXI) Frequently Asked Questions
What is GTX's stock symbol?
GTX trades on the NASDAQ under the ticker symbol "GTXI."
How were GTX's earnings last quarter?
GTx, Inc. (NASDAQ:GTXI) announced its quarterly earnings data on Tuesday, August, 14th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43). View GTX's Earnings History.
When is GTX's next earnings date?
What price target have analysts set for GTXI?
2 analysts have issued 12-month price objectives for GTX's shares. Their predictions range from $17.00 to $45.00. On average, they expect GTX's stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 1,631.8% from the stock's current price. View Analyst Price Targets for GTX.
What is the consensus analysts' recommendation for GTX?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GTX in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GTX.
Who are some of GTX's key competitors?
Some companies that are related to GTX include Molecular Templates (MTEM), Syndax Pharmaceuticals (SNDX), DURECT (DRRX), Intec Pharma (NTEC), Processa Pharmaceuticals (PCSA), Eleven Biotherapeutics (EBIO), Nature's Sunshine Products (NATR), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Spero Therapeutics (SPRO), VERONA PHARMA P/S (VRNA), Ovid Therapeutics (OVID), ContraFect (CFRX), Avadel Pharmaceuticals (AVDL), Lannett (LCI) and Recro Pharma (REPH).
Who are GTX's key executives?
GTX's management team includes the folowing people:
- Dr. Robert James Wills Ph.D., Exec. Chairman (Age 64)
- Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 55)
- Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 69)
- Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 43)
- Dr. Diane C. Young, VP & Chief Medical Officer (Age 61)
How do I buy shares of GTX?
Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GTX's stock price today?
One share of GTXI stock can currently be purchased for approximately $1.79.
How big of a company is GTX?
GTX has a market capitalization of $43.04 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe.
What is GTX's official website?
How can I contact GTX?
GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]
MarketBeat Community Rating for GTX (NASDAQ GTXI)
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
